{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T07:07:08Z","timestamp":1794553628031,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Foundation","award":["DGE1644868"],"award-info":[{"award-number":["DGE1644868"]}]},{"name":"National Science Foundation","award":["1106401"],"award-info":[{"award-number":["1106401"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL138252-01"],"award-info":[{"award-number":["HL138252-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1T32GM144291"],"award-info":[{"award-number":["1T32GM144291"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare, fatal genetic disease that accelerates atherosclerosis. With a limited pool of HGPS patients, clinical trials face unique challenges and require reliable preclinical testing. We previously reported a 3D tissue engineered blood vessel (TEBV) microphysiological system fabricated with iPSC-derived vascular cells from HGPS patients. HGPS TEBVs exhibit features of HGPS atherosclerosis including loss of smooth muscle cells, reduced vasoactivity, excess extracellular matrix (ECM) deposition, inflammatory marker expression, and calcification. We tested the effects of HGPS therapeutics Lonafarnib and Everolimus separately and together, currently in Phase I\/II clinical trial, on HGPS TEBVs. Everolimus decreased reactive oxygen species levels, increased proliferation, reduced DNA damage in HGPS vascular cells, and improved vasoconstriction in HGPS TEBVs. Lonafarnib improved shear stress response of HGPS iPSC-derived endothelial cells (viECs) and reduced ECM deposition, inflammation, and calcification in HGPS TEBVs. Combination treatment with Lonafarnib and Everolimus produced additional benefits such as improved endothelial and smooth muscle\u00a0marker expression and reduced apoptosis, as well as increased TEBV vasoconstriction and vasodilation. These results suggest that a combined trial of both drugs may provide cardiovascular benefits beyond Lonafarnib, if the Everolimus dose can be tolerated.<\/jats:p>","DOI":"10.1038\/s41598-023-32035-3","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T10:04:58Z","timestamp":1679997898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lonafarnib and everolimus reduce pathology in iPSC-derived tissue engineered blood vessel model of Hutchinson-Gilford Progeria Syndrome"],"prefix":"10.1038","volume":"13","author":[{"given":"Nadia O.","family":"Abutaleb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Atchison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Bedapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Shores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yantenew","family":"Gete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Truskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"32035_CR1","unstructured":"Gordon, L. B., Brown, W. T. & Collins, F. S. in GeneReviews\u00ae (eds M. Adam, P. et al.) (University of Washington, 2019)."},{"key":"32035_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1042\/BST20170141","volume":"45","author":"C Strandgren","year":"2017","unstructured":"Strandgren, C., Rev\u00eachon, G., Carvajal, A. S. & Eriksson, M. Emerging candidate treatment strategies for Hutchinson-Gilford progeria syndrome. Biochem. Soc. Trans. 45, 1279\u20131293. https:\/\/doi.org\/10.1042\/BST20170141 (2017).","journal-title":"Biochem. Soc. Trans."},{"key":"32035_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1001\/jama.2018.3264","volume":"319","author":"LB Gordon","year":"2018","unstructured":"Gordon, L. B. et al. Association of lonafarnib treatment vs no treatment with mortality rate in patients with hutchinson-gilford progeria syndrome. JAMA 319, 1687\u20131695. https:\/\/doi.org\/10.1001\/jama.2018.3264 (2018).","journal-title":"JAMA"},{"key":"32035_CR4","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1161\/atvbaha.110.209460","volume":"30","author":"M Olive","year":"2010","unstructured":"Olive, M. et al. Cardiovascular pathology in hutchinson-gilford progeria: Correlation with the vascular pathology of aging. Arterioscler. Thromb. Vasc. Biol. 30, 2301\u20132309. https:\/\/doi.org\/10.1161\/atvbaha.110.209460 (2010).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"32035_CR5","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1056\/NEJMoa0706898","volume":"358","author":"MA Merideth","year":"2008","unstructured":"Merideth, M. A. et al. Phenotype and course of hutchinson-gilford progeria syndrome. N. Engl. J. Med. 358, 592\u2013604. https:\/\/doi.org\/10.1056\/NEJMoa0706898 (2008).","journal-title":"N. Engl. J. Med."},{"key":"32035_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1054-8807(98)00023-4","volume":"8","author":"WE Stehbens","year":"1999","unstructured":"Stehbens, W. E., Wakefield, S. J., Gilbert-Barness, E., Olson, R. E. & Ackerman, J. Histological and ultrastructural features of atherosclerosis in progeria. Cardiovasc. Pathol. 8, 29\u201339. https:\/\/doi.org\/10.1016\/S1054-8807(98)00023-4 (1999).","journal-title":"Cardiovasc. Pathol."},{"key":"32035_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1054-8807(01)00069-2","volume":"10","author":"WE Stehbens","year":"2001","unstructured":"Stehbens, W. E., Delahunt, B., Shozawa, T. & Gilbert-Barness, E. Smooth muscle cell depletion and collagen types in progeric arteries. Cardiovasc. Pathol. 10, 133\u2013136. https:\/\/doi.org\/10.1016\/S1054-8807(01)00069-2 (2001).","journal-title":"Cardiovasc. Pathol."},{"key":"32035_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/CIRCULATIONAHA.116.022965","volume":"134","author":"FS Collins","year":"2016","unstructured":"Collins, F. S. Seeking a cure for one of the rarest diseases: Progeria. Circulation 134, 126\u2013129. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.022965 (2016).","journal-title":"Circulation"},{"key":"32035_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/scitranslmed.3002847","volume":"3","author":"FG Osorio","year":"2011","unstructured":"Osorio, F. G. et al. Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med. 3, 106\u2013107. https:\/\/doi.org\/10.1126\/scitranslmed.3002847 (2011).","journal-title":"Sci. Transl. Med."},{"key":"32035_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.stemcr.2020.01.005","volume":"14","author":"L Atchison","year":"2020","unstructured":"Atchison, L. et al. iPSC-derived endothelial cells affect vascular function in a tissue-engineered blood vessel model of hutchinson-gilford progeria syndrome. Stem Cell Rep. 14, 325\u2013337. https:\/\/doi.org\/10.1016\/j.stemcr.2020.01.005 (2020).","journal-title":"Stem Cell Rep."},{"key":"32035_CR11","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1038\/s41467-020-19197-8","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Modeling early stage atherosclerosis in a primary human vascular microphysiological system. Nat. Comm. 11, 5426. https:\/\/doi.org\/10.1038\/s41467-020-19197-8 (2020).","journal-title":"Nat. Comm."},{"key":"32035_CR12","doi-asserted-by":"publisher","first-page":"2000428","DOI":"10.1002\/adbi.202000428","volume":"5","author":"JH Lee","year":"2021","unstructured":"Lee, J. H. et al. Emulating early atherosclerosis in a vascular microphysiological system using branched tissue-engineered blood vessels. Adv. Biol. 5, 2000428. https:\/\/doi.org\/10.1002\/adbi.202000428 (2021).","journal-title":"Adv. Biol."},{"key":"32035_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1172\/JCI121297","volume":"129","author":"S Osmanagic-Myers","year":"2019","unstructured":"Osmanagic-Myers, S. et al. Endothelial progerin expression causes cardiovascular pathology through an impaired mechanoresponse. J. Clin. Investig. 129, 531\u2013545. https:\/\/doi.org\/10.1172\/JCI121297 (2019).","journal-title":"J. Clin. Investig."},{"key":"32035_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2010.12.002","volume":"8","author":"J Zhang","year":"2011","unstructured":"Zhang, J. et al. A human iPSC model of hutchinson gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8, 31\u201345. https:\/\/doi.org\/10.1016\/j.stem.2010.12.002 (2011).","journal-title":"Cell Stem Cell"},{"key":"32035_CR15","doi-asserted-by":"publisher","first-page":"16666","DOI":"10.1073\/pnas.1202529109","volume":"109","author":"LB Gordon","year":"2012","unstructured":"Gordon, L. B. et al. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. 109, 16666\u201316671. https:\/\/doi.org\/10.1073\/pnas.1202529109 (2012).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32035_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jpeds.2004.10.064","volume":"146","author":"LB Gordon","year":"2005","unstructured":"Gordon, L. B., Harten, I. A., Patti, M. E. & Lichtenstein, A. H. Reduced adiponectin and HDL cholesterol without elevated C-reactive protein: Clues to the biology of premature atherosclerosis in Hutchinson-Gilford Progeria Syndrome. J. Pediatr. 146, 336\u2013341. https:\/\/doi.org\/10.1016\/j.jpeds.2004.10.064 (2005).","journal-title":"J. Pediatr."},{"key":"32035_CR17","doi-asserted-by":"publisher","first-page":"10291","DOI":"10.1073\/pnas.0504641102","volume":"102","author":"SH Yang","year":"2005","unstructured":"Yang, S. H. et al. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc. Natl. Acad. Sci. 102, 10291\u201310296. https:\/\/doi.org\/10.1073\/pnas.0504641102 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32035_CR18","doi-asserted-by":"publisher","first-page":"12873","DOI":"10.1073\/pnas.0505767102","volume":"102","author":"JI Toth","year":"2005","unstructured":"Toth, J. I. et al. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc. Natl. Acad. Sci. 102, 12873\u201312878. https:\/\/doi.org\/10.1073\/pnas.0505767102 (2005).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32035_CR19","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/hmg\/ddi326","volume":"14","author":"MW Glynn","year":"2005","unstructured":"Glynn, M. W. & Glover, T. W. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 14, 2959\u20132969. https:\/\/doi.org\/10.1093\/hmg\/ddi326 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"32035_CR20","doi-asserted-by":"publisher","first-page":"12879","DOI":"10.1073\/pnas.0506001102","volume":"102","author":"BC Capell","year":"2005","unstructured":"Capell, B. C. et al. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA. 102, 12879\u201312884. https:\/\/doi.org\/10.1073\/pnas.0506001102 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"32035_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbalip.2007.11.003","volume":"1781","author":"SH Yang","year":"2008","unstructured":"Yang, S. H., Qiao, X., Fong, L. G. & Young, S. G. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. Biochimica et Biophysica Acta BBA Mol. Cell Biol. Lipids 1781, 36\u201339. https:\/\/doi.org\/10.1016\/j.bbalip.2007.11.003 (2008).","journal-title":"Biochimica et Biophysica Acta BBA Mol. Cell Biol. Lipids"},{"key":"32035_CR22","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1172\/JCI28968","volume":"116","author":"SH Yang","year":"2006","unstructured":"Yang, S. H. et al. A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest. 116, 2115\u20132121. https:\/\/doi.org\/10.1172\/JCI28968 (2006).","journal-title":"J. Clin. Invest."},{"key":"32035_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1172\/JCI27125","volume":"116","author":"LG Fong","year":"2006","unstructured":"Fong, L. G. et al. Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J. Clin. Invest. 116, 743\u2013752. https:\/\/doi.org\/10.1172\/JCI27125 (2006).","journal-title":"J. Clin. Invest."},{"key":"32035_CR24","doi-asserted-by":"publisher","first-page":"15902","DOI":"10.1073\/pnas.0807840105","volume":"105","author":"BC Capell","year":"2008","unstructured":"Capell, B. C. et al. A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc. Natl. Acad. Sci. USA 105, 15902\u201315907 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"32035_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/circulationaha.113.008285","volume":"130","author":"LB Gordon","year":"2014","unstructured":"Gordon, L. B. et al. Impact of farnesylation inhibitors on survival in hutchinson-gilford progeria syndrome. Circulation 130, 27\u201334. https:\/\/doi.org\/10.1161\/circulationaha.113.008285 (2014).","journal-title":"Circulation"},{"key":"32035_CR26","doi-asserted-by":"publisher","first-page":"89ra58","DOI":"10.1126\/scitranslmed.3002346","volume":"3","author":"K Cao","year":"2011","unstructured":"Cao, K. et al. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in hutchinson-gilford progeria syndrome cells. Sci. Transl. Med. 3, 89ra58. https:\/\/doi.org\/10.1126\/scitranslmed.3002346 (2011).","journal-title":"Sci. Transl. Med."},{"key":"32035_CR27","doi-asserted-by":"publisher","first-page":"e0168988","DOI":"10.1371\/journal.pone.0168988","volume":"11","author":"D Gabriel","year":"2016","unstructured":"Gabriel, D., Gordon, L. B. & Djabali, K. Temsirolimus partially rescues the hutchinson-gilford progeria cellular phenotype. PLoS ONE 11, e0168988. https:\/\/doi.org\/10.1371\/journal.pone.0168988 (2016).","journal-title":"PLoS ONE"},{"key":"32035_CR28","doi-asserted-by":"publisher","first-page":"e13457","DOI":"10.1111\/acel.13457","volume":"20","author":"WA Cabral","year":"2021","unstructured":"Cabral, W. A. et al. Genetic reduction of mTOR extends lifespan in a mouse model of Hutchinson-Gilford Progeria syndrome. Aging Cell 20, e13457. https:\/\/doi.org\/10.1111\/acel.13457 (2021).","journal-title":"Aging Cell"},{"key":"32035_CR29","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1073\/pnas.1802811115","volume":"115","author":"AJ DuBose","year":"2018","unstructured":"DuBose, A. J. et al. Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc. Natl. Acad. Sci. 115, 4206. https:\/\/doi.org\/10.1073\/pnas.1802811115 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32035_CR30","doi-asserted-by":"publisher","first-page":"8963","DOI":"10.1073\/pnas.0402943101","volume":"101","author":"RD Goldman","year":"2004","unstructured":"Goldman, R. D. et al. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. 101, 8963\u20138968. https:\/\/doi.org\/10.1073\/pnas.0402943101 (2004).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"32035_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/circresaha.115.306301","volume":"118","author":"MA Gimbrone","year":"2016","unstructured":"Gimbrone, M. A. & Garc\u00eda-Carde\u00f1a, G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 118, 620\u2013636. https:\/\/doi.org\/10.1161\/circresaha.115.306301 (2016).","journal-title":"Circ. Res."},{"key":"32035_CR32","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1080\/15384101.2017.1364324","volume":"16","author":"H Nakajima","year":"2017","unstructured":"Nakajima, H. & Mochizuki, N. Flow pattern-dependent endothelial cell responses through transcriptional regulation. Cell Cycle 16, 1893\u20131901. https:\/\/doi.org\/10.1080\/15384101.2017.1364324 (2017).","journal-title":"Cell Cycle"},{"key":"32035_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.arr.2016.06.007","volume":"33","author":"S Gonzalo","year":"2017","unstructured":"Gonzalo, S., Kreienkamp, R. & Askjaer, P. Hutchinson-Gilford Progeria Syndrome: A premature aging disease caused by LMNA gene mutations. Ageing Res. Rev. 33, 18\u201329. https:\/\/doi.org\/10.1016\/j.arr.2016.06.007 (2017).","journal-title":"Ageing Res. Rev."},{"key":"32035_CR34","doi-asserted-by":"publisher","first-page":"40722","DOI":"10.1074\/jbc.M112.381509","volume":"287","author":"M Kim","year":"2012","unstructured":"Kim, M. et al. Laminar flow activation of ERK5 protein in vascular endothelium leads to atheroprotective effect via NF-E2-related factor 2 (Nrf2) activation. J. Biol. Chem. 287, 40722\u201340731. https:\/\/doi.org\/10.1074\/jbc.M112.381509 (2012).","journal-title":"J. Biol. Chem."},{"key":"32035_CR35","doi-asserted-by":"publisher","first-page":"8168","DOI":"10.1038\/s41598-017-08632-4","volume":"7","author":"L Atchison","year":"2017","unstructured":"Atchison, L., Zhang, H., Cao, K. & Truskey, G. A. A tissue engineered blood vessel model of hutchinson-gilford progeria syndrome using human iPSC-derived smooth muscle cells. Sci. Rep. 7, 8168. https:\/\/doi.org\/10.1038\/s41598-017-08632-4 (2017).","journal-title":"Sci. Rep."},{"key":"32035_CR36","doi-asserted-by":"publisher","first-page":"963","DOI":"10.4161\/auto.20186","volume":"8","author":"MT Rosenfeldt","year":"2012","unstructured":"Rosenfeldt, M. T., Nixon, C., Liu, E., Mah, L. Y. & Ryan, K. M. Analysis of macroautophagy by immunohistochemistry. Autophagy 8, 963\u2013969. https:\/\/doi.org\/10.4161\/auto.20186 (2012).","journal-title":"Autophagy"},{"key":"32035_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.4161\/auto.8.1.18331","volume":"8","author":"JJ Graziotto","year":"2012","unstructured":"Graziotto, J. J., Cao, K., Collins, F. S. & Krainc, D. Rapamycin activates autophagy in Hutchinson-Gilford progeria syndrome. Autophagy 8, 147\u2013151. https:\/\/doi.org\/10.4161\/auto.8.1.18331 (2012).","journal-title":"Autophagy"},{"key":"32035_CR38","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.18632\/aging.102941","volume":"12","author":"X Mao","year":"2020","unstructured":"Mao, X., Bharti, P., Thaivalappil, A. & Cao, K. Peroxisomal abnormalities and catalase deficiency in Hutchinson-Gilford Progeria Syndrome. Aging 12, 5195\u20135208. https:\/\/doi.org\/10.18632\/aging.102941 (2020).","journal-title":"Aging"},{"key":"32035_CR39","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s10522-018-9758-4","volume":"19","author":"MU Bikkul","year":"2018","unstructured":"Bikkul, M. U. et al. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts. Biogerontology 19, 579\u2013602. https:\/\/doi.org\/10.1007\/s10522-018-9758-4 (2018).","journal-title":"Biogerontology"},{"key":"32035_CR40","doi-asserted-by":"publisher","first-page":"e13175","DOI":"10.1111\/acel.13175","volume":"19","author":"W-F Lai","year":"2020","unstructured":"Lai, W.-F. & Wong, W.-T. Progress and trends in the development of therapies for Hutchinson-Gilford progeria syndrome. Aging Cell 19, e13175. https:\/\/doi.org\/10.1111\/acel.13175 (2020).","journal-title":"Aging Cell"},{"key":"32035_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1096\/fj.07-8598com","volume":"22","author":"Y Liu","year":"2008","unstructured":"Liu, Y. et al. Involvement of xeroderma pigmentosum group A (XPA) in progeria arising from defective maturation of prelamin A. FASEB J. 22, 603\u2013611. https:\/\/doi.org\/10.1096\/fj.07-8598com (2008).","journal-title":"FASEB J."},{"key":"32035_CR42","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1242\/jcs.03263","volume":"119","author":"Y Liu","year":"2006","unstructured":"Liu, Y., Rusinol, A., Sinensky, M., Wang, Y. & Zou, Y. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J. Cell Sci. 119, 4644. https:\/\/doi.org\/10.1242\/jcs.03263 (2006).","journal-title":"J. Cell Sci."},{"key":"32035_CR43","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nm1266","volume":"11","author":"B Liu","year":"2005","unstructured":"Liu, B. et al. Genomic instability in laminopathy-based premature aging. Nat. Med. 11, 780\u2013785. https:\/\/doi.org\/10.1038\/nm1266 (2005).","journal-title":"Nat. Med."},{"key":"32035_CR44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.cell.2016.05.017","volume":"165","author":"N Kubben","year":"2016","unstructured":"Kubben, N. et al. Repression of the antioxidant NRF2 pathway in premature aging. Cell 165, 1361\u20131374. https:\/\/doi.org\/10.1016\/j.cell.2016.05.017 (2016).","journal-title":"Cell"},{"key":"32035_CR45","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/acel.12434","volume":"15","author":"Z-M Xiong","year":"2016","unstructured":"Xiong, Z.-M. et al. Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell 15, 279\u2013290. https:\/\/doi.org\/10.1111\/acel.12434 (2016).","journal-title":"Aging Cell"},{"key":"32035_CR46","doi-asserted-by":"publisher","first-page":"e12936","DOI":"10.1111\/acel.12936","volume":"18","author":"L del Campo","year":"2019","unstructured":"del Campo, L. et al. Vascular smooth muscle cell-specific progerin expression in a mouse model of Hutchinson-Gilford progeria syndrome promotes arterial stiffness: Therapeutic effect of dietary nitrite. Aging Cell 18, e12936. https:\/\/doi.org\/10.1111\/acel.12936 (2019).","journal-title":"Aging Cell"},{"key":"32035_CR47","doi-asserted-by":"publisher","first-page":"eaay5556","DOI":"10.1126\/sciadv.aay5556","volume":"6","author":"S Sun","year":"2020","unstructured":"Sun, S. et al. Vascular endothelium\u2013targeted Sirt7 gene therapy rejuvenates blood vessels and extends life span in a Hutchinson-Gilford progeria model. Sci. Adv. 6, eaay5556. https:\/\/doi.org\/10.1126\/sciadv.aay5556 (2020).","journal-title":"Sci. Adv."},{"key":"32035_CR48","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/cells9051201","volume":"9","author":"G Bidault","year":"2020","unstructured":"Bidault, G. et al. Progerin expression induces inflammation, oxidative stress and senescence in human coronary endothelial cells. Cells 9, 1201\u20131217 (2020).","journal-title":"Cells"},{"key":"32035_CR49","doi-asserted-by":"publisher","first-page":"e13388","DOI":"10.1111\/acel.13388","volume":"20","author":"YG Gete","year":"2021","unstructured":"Gete, Y. G. et al. Mechanisms of angiogenic incompetence in Hutchinson-Gilford progeria via downregulation of endothelial NOS. Aging Cell 20, e13388. https:\/\/doi.org\/10.1111\/acel.13388 (2021).","journal-title":"Aging Cell"},{"key":"32035_CR50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.bpj.2022.01.004","volume":"121","author":"BE Danielsson","year":"2022","unstructured":"Danielsson, B. E. et al. Progerin-expressing endothelial cells are unable to adapt to shear stress. Biophys. J. 121, 620\u2013628. https:\/\/doi.org\/10.1016\/j.bpj.2022.01.004 (2022).","journal-title":"Biophys. J."},{"key":"32035_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1126\/science.1127168","volume":"312","author":"P Scaffidi","year":"2006","unstructured":"Scaffidi, P. & Misteli, T. Lamin A-dependent nuclear defects in human aging. Science 312, 1059\u20131063. https:\/\/doi.org\/10.1126\/science.1127168 (2006).","journal-title":"Science"},{"key":"32035_CR52","doi-asserted-by":"publisher","first-page":"9143","DOI":"10.18632\/aging.202835","volume":"13","author":"LB Gordon","year":"2021","unstructured":"Gordon, L. B. et al. The progeria research foundation 10th international scientific workshop; researching possibilities, ExTENding lives\u2014Webinar version scientific summary. Aging 13, 9143\u20139151. https:\/\/doi.org\/10.18632\/aging.202835 (2021).","journal-title":"Aging"},{"key":"32035_CR53","doi-asserted-by":"crossref","unstructured":"Shipkova, M. et al. Therapeutic drug monitoring of everolimus: A consensus report. Therapeutic Drug Monitoring. 38, 143\u2013169 (2016).","DOI":"10.1097\/FTD.0000000000000260"},{"key":"32035_CR54","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s10637-021-01131-4","volume":"39","author":"M Fukudo","year":"2021","unstructured":"Fukudo, M., Ishibashi, K. & Kitada, M. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. Invest. New Drugs 39, 1707\u20131715. https:\/\/doi.org\/10.1007\/s10637-021-01131-4 (2021).","journal-title":"Invest. New Drugs"},{"key":"32035_CR55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell, A. et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur. J. Clin. Pharmacol. 77, 441\u2013464. https:\/\/doi.org\/10.1007\/s00228-020-03014-8 (2021).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"32035_CR56","doi-asserted-by":"publisher","first-page":"e022123","DOI":"10.1161\/JAHA.121.022123","volume":"10","author":"J Gomez-Lara","year":"2021","unstructured":"Gomez-Lara, J. et al. Coronary endothelium-dependent vasomotor function after drug-eluting stent and bioresorbable scaffold implantation. J. Am. Heart Assoc. 10, e022123. https:\/\/doi.org\/10.1161\/JAHA.121.022123 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"32035_CR57","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1111\/ajt.12669","volume":"14","author":"YP Jin","year":"2014","unstructured":"Jin, Y. P., Valenzuela, N. M., Ziegler, M. E., Rozengurt, E. & Reed, E. F. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am. J. Transpl. 14, 806\u2013819. https:\/\/doi.org\/10.1111\/ajt.12669 (2014).","journal-title":"Am. J. Transpl."},{"key":"32035_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1473-3099(15)00074-2","volume":"15","author":"C Koh","year":"2015","unstructured":"Koh, C. et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet. Infect. Dis 15, 1167\u20131174. https:\/\/doi.org\/10.1016\/S1473-3099(15)00074-2 (2015).","journal-title":"Lancet. Infect. Dis"},{"key":"32035_CR59","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/ncb3205","volume":"17","author":"C Patsch","year":"2015","unstructured":"Patsch, C. et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat. Cell Biol. 17, 994\u20131003. https:\/\/doi.org\/10.1038\/ncb3205 (2015).","journal-title":"Nat. Cell Biol."},{"key":"32035_CR60","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.xpro.2021.100394","volume":"2","author":"NO Abutaleb","year":"2021","unstructured":"Abutaleb, N. O. & Truskey, G. A. Differentiation and characterization of human iPSC-derived vascular endothelial cells under physiological shear stress. STAR Protocols 2, 100394. https:\/\/doi.org\/10.1016\/j.xpro.2021.100394 (2021).","journal-title":"STAR Protocols"},{"key":"32035_CR61","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jbm.a.10403","volume":"64A","author":"AB Mathur","year":"2003","unstructured":"Mathur, A. B., Truskey, G. A. & Reichert, W. M. Synergistic effect of high-affinity binding and flow preconditioning on endothelial cell adhesion. J. Biomed. Mater. Res. Part A 64A, 155\u2013163. https:\/\/doi.org\/10.1002\/jbm.a.10403 (2003).","journal-title":"J. Biomed. Mater. Res. Part A"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32035-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32035-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T10:16:19Z","timestamp":1679998579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32035-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32035"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32035-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"22 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5032"}}